+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Innovations in Drug Discovery and Development

  • PDF Icon


  • 15 Pages
  • March 2018
  • Region: Global
  • Frost & Sullivan
  • ID: 4519613

This Drug Discovery TechVision Opportunity Engine (TOE) depicts the current landscape and the new life sciences trends across drug discovery. This issue is focused on novel drug discovery platforms, including intelligent discovery and prodrug technologies for cancer immunotherapies and adjacent cell therapies. Several 'priority review' and 'orphan drug designation' cases are analyzed. The corresponding clinical trials scenario is also depicted.

The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.

The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Table of Contents

1. Recent Innovations in Drug Discovery and Therapeutics
Advances in NK Cell Cancer Immunotherapy
Advancing the First Wave of Red Blood Cell Therapies
Targeting Critical Pathways in Autoimmune Diseases
Advancing Clinical Studies of PB1046
Intelligent Drug Discovery Platform
Using Prodrug Platform to Improve Drug Properties of Approved Drugs
Only Approved Immunotherapy Till Date for Unresectable Stage III Non-small Cell Lung Cancer
Priority Review Designation for Non-Metastatic Castration-Resistant Prostate Cancer
Orphan Drug Designation for Pancreatic Cancer Therapeutics

2. Drug Discovery Technology Focus and Trends
Clinical Trial Analysis
Industry Interactions